An Act to amend and reenact §§ 18.2-251.1:2 and 32.1-127 of the Code of Virginia, relating to medical cannabis; administration to terminally ill patients; report.
HB75 amends Virginia law to expand protections for the possession, storage, dispensing, and administration of medical cannabis oil in certain health care and residential care settings. Specifically, it shields employees of hospitals, nursing homes, hospice and hospice facilities, and assisted living facilities from prosecution under specified drug laws when they handle cannabis oil for a patient or resident who has a valid written certification under Virginia’s medical cannabis program.
The bill also amends the state’s hospital and nursing facility regulatory statute, § 32.1-127, though the text provided shows the broader regulatory framework rather than a targeted cannabis-specific change. In the context of the bill caption, the measure is tied to medical cannabis administration for terminally ill patients and includes a report component, indicating legislative interest in how cannabis oil is used in end-of-life care settings and how facilities should be regulated or monitored in that context.
The bill primarily affects §§ 18.2-251.1:2 and 32.1-127 of the Code of Virginia. It creates or clarifies a limited immunity from prosecution for covered facility staff who possess or distribute cannabis oil for certified patients or residents, reducing legal risk for hospitals, nursing homes, hospice providers, hospice facilities, and assisted living facilities that participate in medical cannabis administration. It also sits within the broader regulatory structure governing health care facilities, potentially influencing facility policies, staff training, and compliance practices related to medical cannabis in patient care settings.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or opposition in the supplied materials. Based on the bill’s enactment and its narrow focus on terminally ill patients and facility staff protections, the overall sentiment appears to have been favorable or at least sufficient to secure passage. The absence of recorded controversy in the provided context suggests the measure may have been viewed as a limited, patient-centered clarification rather than a broad expansion of cannabis policy.
The main potential point of contention is the intersection of medical cannabis with existing criminal drug laws and facility-level compliance obligations. Supporters would likely emphasize compassionate end-of-life care and legal protection for health care workers, while opponents or cautious stakeholders could raise concerns about diversion, facility liability, staff training, and whether cannabis administration in institutional settings should be expanded. Because no transcripts were provided, it is not possible to attribute specific arguments to named individuals or groups.